SCHEMBL2860150

SCHEMBL2860150

C=CCOc1cc(OCC=C)c(C(=O)c2ccc(O)c(OC)c2)c(C(CC)C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.44
SLC22A8 Q8TCC7 1/20 0.44
HTT P42858 1/20 0.41
HSD17B2 P37059 1/20 0.40
PTPN1 P18031 2/20 0.39
BLM P54132 2/20 0.39
CYP1A2 P05177 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TSHR P16473 1/20 0.38
PDE4B Q07343 1/20 0.38
BCHE P06276 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865481 0.93 KDM4E (0.45) KDM4ESLC22A6SLC22A8PTPN1RAB9A
SCHEMBL2861694 0.91 KDM4E (0.45) KDM4ESLC22A6SLC22A8HTTHSD17B2
SCHEMBL2856378 0.89 FLT3 (0.44) KDM4EPTPN1MEN1RAB9AKMT2A
SCHEMBL2862952 0.88 KDM4E (0.36) KDM4EPTPN1RAB9APOLBGAA
SCHEMBL2858279 0.88 KDM4E (0.44) KDM4ECYP1A2KMT2AGAATSHR
SCHEMBL2861776 0.88 KDM4E (0.44) KDM4ERAB9APOLBTSHRPDE4B
SCHEMBL2859124 0.88 KDM4E (0.49) KDM4EMEN1RAB9AKMT2APOLB
SCHEMBL2863757 0.88 KDM4E (0.49) KDM4EMEN1KMT2APOLBGAA
SCHEMBL2867272 0.88 KDM4E (0.39) KDM4EPTPN1RAB9APOLBGAA
SCHEMBL5493553 0.86 MAPT (0.48) KDM4ERAB9AKMT2APOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1642880-B1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KIRIN CO LTD (JP) 2013-09-04 EP disclosed
US-7767693-B2 Hsp90 family protein inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-08-03 US disclosed
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-10-01 US disclosed
US-7538224-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 US disclosed
EP-1642880-A1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032532-A1 Hsp90 family protein inhibitors HSP90AB1, HSP90B1, HSP90AB2P KDM4E 2968/4885SLC22A6 1282/4885SLC22A8 1843/4885
US-20090247522-A1 Hsp90 FAMILY PROTEIN INHIBITORS HSP90AB1, HSP90B1, HSP90AB2P KDM4E 2968/4885SLC22A6 1282/4885SLC22A8 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.